Innovation in Nano Science and
OmegaGenesis is a biotechnology company based in California and
founded in February 2008 with the purpose of creating therapeutic
applications based on rare earth nano material discovery. The
Company's research is focused on nano-scale materials that promote
or inhibit angiogenesis, the growth of new blood vessels.
OmegaGenesis is developing suitable nano-materials to manage human
body functions at nano scale (the cell and sub-cell level)
accelerating cellular-based biologic therapies where the growth of
blood vessels determines the therapeutic outcome. These
nano-materials will enable Physicians to treat disease at
sub-cellular level in a non-destructive manner instead of treating
the disease at the organ or tissue level.
Omega Genesis has licensed technology from Mayo Clinic involving a
number of nano-materials made of rare earth elements that promote
angiogenesis. OmegaGenesis is translating the fundamental research
conducted at Mayo Clinic into the product development process and
ultimately medical applications.
The OmegaGenesis nanotechnology platform has broad therapeutic
potential for a variety of medical applications. The Company's
nanotechnology supplements the natural human angiogenesis process
to re-enable processes that are dormant or diminished. OmegaGenesis
is the first to use nutrient enhancement through new capillary
growth to heal wounds and tissues by activating dormant cells.
Rare earth element nano-materials that promote angiogenesis can
potentially be used for wound healing, the treatment of diabetic
foot ulcers and thus decreasing the frequency of amputations, hair
re-growth, repair of ischemic heart damage and promoting bone
The core technology platform provides for future development in the
area of anti-angiogenesis applications. Anti-angiogenic nano
materials may effectively treat cancer by depriving the tumor cells
of the oxygen and nutrition needed to grow and spread to
neighboring tissues. Rare earth nano materials may also have
additional applications in medical imaging and diagnostics.
"Every 30 seconds someone loses a leg because of diabetes and a
non-healing wound. Most of these occur because of wounds. This
technology may have the potential to alter the balance of power
between healing and amputation."
David G. Armstrong, DPM, MD, PhD, Professor of Surgery, University
of Arizona College of Medicine
"Two of the most common causes of death are heart attacks and
strokes. Both of these diseases are increased in patients with
diabetes. The technology OmegaGenesis is developing has the
potential to enhance diabetic wound healing and may prevent death
and disability in these two devastating diseases."
Harold F. Dvorak, MD, Mallinckrodt Distinguished Professor of
Pathology Beth Israel Deaconess Medical Center, Boston, MA